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Salmonella Typhi is a human host-restricted pathogen that 
is responsible for typhoid fever in approximately 10.9 mil-
lion people annually1. The typhoid toxin is postulated to have 
a central role in disease pathogenesis, the establishment of 
chronic infection and human host restriction2–6. However, its 
precise role in typhoid disease in humans is not fully defined. 
We studied the role of typhoid toxin in acute infection using 
a randomized, double-blind S. Typhi human challenge model7. 
Forty healthy volunteers were randomized (1:1) to oral chal-
lenge with 104 colony-forming units of wild-type or an isogenic 
typhoid toxin deletion mutant (TN) of S. Typhi. We observed 
no significant difference in the rate of typhoid infection (fever 
≥38 °C for ≥12 h and/or S. Typhi bacteremia) between partici-
pants challenged with wild-type or TN S. Typhi (15 out of 21 
(71%) versus 15 out of 19 (79%); P = 0.58). The duration of 
bacteremia was significantly longer in participants challenged 
with the TN strain compared with wild-type (47.6 hours 
(28.9–97.0) versus 30.3(3.6–49.4); P ≤ 0.001). The clinical 
syndrome was otherwise indistinguishable between wild-type 
and TN groups. These data suggest that the typhoid toxin 
is not required for infection and the development of early 
typhoid fever symptoms within the context of a human chal-
lenge model. Further clinical data are required to assess the 
role of typhoid toxin in severe disease or the establishment of 
bacterial carriage.
Several preclinical studies have described the structure and func-
tion of the typhoid toxin in  vitro and in small-animal models2–6. 
Systemic administration of typhoid toxin to C57BL/6 mice results in 
the reproduction of many characteristic symptoms of typhoid fever; 
other studies have suggested that typhoid toxin may contribute to 
the establishment of chronic infection4,5. It remains unclear how the 
surrogate end points of illness in mice—such as lethargy, weight 
loss, behavioral and motor changes3,8—are representative of acute 
typhoid fever in humans. The toxin is also encoded by >40 clade B 
non-typhoidal Salmonella (NTS) serovars that display a broad host 
range and a distinct clinical phenotype to S. Typhi and Paratyphi9–11, 
although some typhoid toxin-expressing NTS serovars appear to 
cause an enteric fever-like syndrome12. Importantly, no previous 
studies have characterized the role of typhoid toxin in a human 
model of disease.
We aimed to characterize the role of typhoid toxin in human 
infection and pathogenesis using an S. Typhi human challenge 
model7. This model has previously been used to test novel live-
attenuated (MO1ZH09) (ref. 13) and Vi-conjugate (Typbar-TCV) 
typhoid vaccines14. We manufactured two challenge strains of S. 
Typhi to good manufacturing practice (GMP) standards. We used 
the wild-type S. Typhi Quailes strain (genotype 3.0.1 (ref. 15)) as the 
parent strain to generate an isogenic typhoid toxin-deficient knock-
out strain (TN), as described previously16. Whole-genome sequenc-
ing confirmed the absence of the typhoid toxin pathogenicity islet 
in the TN strain (Supplementary Information). The wild-type and 
TN strains harbored no other differences in relation to known key 
virulence factors (Supplementary Information). In particular, there 
were no differences identified in Salmonella pathogenicity island 7, a 
region encoding genes required for expression of the Vi-capsule—a 
key virulence factor in the pathogenesis of S. Typhi. Differences 
between strains were confined to highly variable regions encoding 
phage proteins, which were not known to impact on bacterial sur-
vival in the environment or persistence in the human host. However, 
deletion of the entire typhoid toxin pathogenicity island was associ-
ated with increased bacterial burden in a mouse model of S. Typhi 
infection, compared with a strain expressing a catalytic mutant of 
typhoid toxin (cdtBH160Q pltBS35A pltAE133A; Fig. 1). Otherwise, the 
wild-type and TN challenge strain variants displayed comparable 
phenotypic properties with regards to Vi-capsule expression, cellu-
lar invasion, in vitro growth characteristics, antibiotic susceptibil-
ity and survival in environmental water and soil samples (data not 
shown). Cell cycle arrest in vitro was observed with the wild-type 
but not the TN strain (Fig. 1).
We enrolled a total of 41 healthy adults (aged 18–60 years) into a 
randomized, double-blind, human challenge study between 10 April 
and 1 August 2017. One volunteer withdrew prior to challenge, 
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and 40 completed the challenge protocol (Extended Data 
Fig. 1). The study was undertaken in a cohort of healthy adult 
volunteers in a setting non-endemic for typhoid fever (Oxford14; 
see the Life Sciences Reporting Summary). Groups were well 
matched at baseline (Extended Data Fig. 2 and Supplementary 
Data). Participants fasted for 90 min before oral challenge with 
1–5 × 104 colony-forming units (CFUs) of either wild-type or TN 
strains administered 2 min after sodium bicarbonate pretreatment 
(Supplementary Information). Study visits were scheduled for 12 h 
after challenge, and then daily for 14 d, when daily blood cultures 
were collected (Fig. 1) (ref. 7). Antibiotic treatment (ciprofloxacin 
500 mg twice daily) was initiated at typhoid diagnosis or at day 14 
for those without illness.
Using the primary composite diagnostic end point of fever 
≥38 °C for ≥12 h and/or S. Typhi bacteremia, we observed no sig-
nificant difference in the rate of typhoid disease between partici-
pants challenged with wild-type or TN strains (15 out of 21 (71%) 
versus 15 out of 19 (79%); relative risk 1.11 (95% confidence interval 
(CI) 0.8–1.6); P = 0.58; Fig. 2 and Supplementary Data). The attack 
rate (ndiagnosed/nchallenged) in the wild-type group met the target range 
of 60–75% and was consistent with earlier studies7,13,14. There was 
no significant difference in the attack rate when we applied alterna-
tive diagnostic criteria (Supplementary Data). The challenge dose 
administered did not impact the outcome of the challenge (Fig. 2). 
Furthermore, there was no significant difference in time to diagno-
sis between wild-type and TN groups (median (interquartile range 
(IQR)) days to diagnosis 7.05 (5.08–8.83) versus 5.25 (5.01–6.14); 
P = 0.23; Fig. 2).
To determine if absence of the typhoid toxin was associated with 
an altered disease phenotype, we compared the clinical profiles 
between challenge groups (Fig. 2). Five participants met the prespec-
ified criteria for severe typhoid fever; of these, one participant was 
randomized to wild-type (1 out of 15; 7%) and four (4 out of 15; 27%; 
P = 0.3) were randomized to TN (Supplementary Data). Two serious 
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Fig. 1 | Trial design. a, Schematic of trial design (Supplementary Information); comparison of wild-type and TN strains. b, Cellular invasion assessed using 
a gentamicin protection assay. MOI = 50, n = 3 independent replicates, two-sided Mann–Whitney U-test. c, Induction of cell cycle arrest in Henle-407 
cells infected with the wild-type or TN strain (MOI = 50). Intoxicated cells show a larger proportion of cells in the G2/M phase of the cell cycle. n = 3 
independent replicates. d, Comparison of the bacterial loads of S. Typhi Quailes typhoid toxin-null mutant (ST-ΔTT, ∆pltB, ∆pltA, ∆cdtB) with S. Typhi 
Quailes typhoid toxin catalytic mutant (ST-CM, cdtBH160Q, pltBS35A, pltAE133A). n = 28, Wilcoxon signed-rank test. The box plots display the median and IQR, 
with the upper whiskers extending to the largest value ≤1.5 × IQR from 75th percentile and the lower whiskers extending to smallest values ≤1.5 × IQR from 
25th percentile. The Fig. 1a images were sourced from Servier Medical Art and reproduced and adapted under a Creative Commons 3.0 unported license29.
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adverse events were reported, neither of which was assessed as 
being related to S. Typhi challenge (Supplementary Information). 
The most common symptoms reported by participants who 
developed typhoid were headache (30 out of 30; 100%), malaise 
(30 out of 30; 100%), anorexia (26 out of 30; 87%) and abdominal 
pain (23 out of 30; 77%; Fig. 2 and Supplementary Information). 
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Fig. 2 | Clinical response to challenge with wild-type and TN S. Typhi. a, Time to diagnosis after challenge. Cumulative proportion of participants meeting 
the composite diagnostic end point defined as S. Typhi bacteremia and/or fever ≥38 C° persisting ≥12 h. Participants not meeting the diagnostic criteria for 
typhoid diagnosis were censored at day 14. log-rank test. b, Challenge dose administered between wild-type and TN challenge groups. Two-sided Mann–
Whitney U-test, nTN = 19, nWild-type = 21. c, Challenge dose administered according to outcome and challenge strain. Mann–Whitney U-test. d, Time to first fever 
>38 °C. e, Fever clearance time categorized according to study group. Kaplan–Meier survival curve showing the cumulative proportion of participants with 
any fever >38 °C by challenge group. Participants with no recorded fever were censored at day 14. log-rank test. f, Cumulative symptom severity scores in all 
participants challenged30; nTN = 19, nWild-type = 21. Two-sided Mann–Whitney U-test. g, Maximum symptom severity score (day 0–21) in participants diagnosed 
with typhoid fever according to study group. Percentage of participants reporting one or more events, graded as mild, moderate or severe30. The box plots 
display the median and IQR, with the upper whiskers extending to largest value ≤1.5 × IQR from the 75th percentile and the lower whiskers extending to the 
smallest values ≤ 1.5 × IQR from the 25th percentile31. The overlaid violin plots illustrate the distribution of the data points and their probability density31.
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Fig. 3 | Microbiological response to challenge with wild-type and TN S. Typhi. a,b, Pattern of stool shedding after TN (a) and wild-type (b) challenge. The 
rows correspond to individual participants. Gray squares, negative sample; brown squares, positive stool culture; white squares = no sample collected. Tx is 
the day of treatment initiation. c, Probability of stool shedding S. Typhi over time after challenge. Samples were classified as culture-positive or culture-
negative for S. Typhi and combined in mixed effects logistic regression models, as described previously18. nWild-type = 21, nTN = 19. d,e, Pattern of bacteremia 
after TN (d) and wild-type (e) challenge. Red squares = positive blood culture. Participants above the dotted lines did not meet the composite criteria for 
typhoid diagnosis. f, Quantitative blood culture at time of typhoid diagnosis. Samples with no colonies were assigned an arbitrary value corresponding 
to half the lower limit of detection (0.05 CFU ml−1). nWild-type = 15, nTN = 15, two-sided Mann–Whitney U-test. g,h, Kaplan–Meier survival curve showing the 
cumulative proportion of participants with bacteremia after challenge (g) and time to S. Typhi bacteremia (h). Participants not meeting the diagnostic 
criteria were censored at day 14. Cumulative proportion of participants with ongoing bacteremia were measured from time of treatment initiation to first 
persistently negative blood culture, according to challenge group. log-rank test. The box plots display the median and IQR, the upper whiskers extending 
to the largest value ≤1.5 × IQR from the 75th percentile and the lower whiskers extending to the smallest values ≤1.5 × IQR from the 25th percentile. The 
overlaid violin plots illustrate the distribution of the data points and their probability density31.
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28 after challenge. nWild-type = 21, nTN = 19, Wilcoxon signed-rank test for within-group comparisons on paired samples. b, Magnitude of ASC response at 
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Fever clearance time was comparable between wild-type and TN 
groups (median (IQR) hours 53.15 (23.0–87.4) versus 44.92 (12–
96.6) hours; P = 0.71; Fig. 2). Laboratory abnormalities (elevated 
C-reactive protein, lymphopenia, neutropenia) were all consis-
tent with the expected presentation of typhoid fever in the field17 
(Extended Data Fig. 3). Overall, the clinical phenotype was compa-
rable between groups.
We next assessed if absence of typhoid toxin was associated with 
altered microbiological end points (Fig. 3). At least one stool culture 
was positive for S. Typhi in 13 out of 21 (62%) participants chal-
lenged with the wild-type strain and 11 out of 19 (58%) challenged 
with the TN strain. The pattern of stool shedding was comparable 
between groups, peaking 24–48 h after challenge, followed by a sec-
ond peak in week 2 (Fig. 3) (ref. 18). There was no difference in the 
probability of shedding over the entire challenge period following 
challenge with TN compared with wild-type (odds ratio 0.64, 95% 
CI 0.17–2.47, P = 0.51). In a humanized mouse model, infection 
with a typhoid toxin-deficient strain of S. Typhi was associated with 
an increased bacterial burden compared with the wild-type strain19. 
Consistent with this observation, the duration of bacteremia was 
significantly longer in participants challenged with the TN strain 
compared with the wild-type strain (47.6 h (28.9–97.0) versus 30.3 
(3.6–49.4); P ≤ 0.001; Fig. 3), although circulating quantitative col-
ony counts did not differ (0.2 CFU ml−1 (0–21) versus 0.55 CFU ml−1 
(0–3); P = 0.44; Fig. 3). We next performed a principal component 
analysis of disease severity, using all clinical, microbiological and 
laboratory measures collected during the course of the challenge 
study. When all participants were included in the analysis, partici-
pants diagnosed with typhoid fever clearly cluster separately from 
individuals who did not develop disease (Extended Data Fig. 4); 
however, there was no clustering of participants by challenge group, 
suggesting that challenge with a typhoid toxin-deficient strain of 
S. Typhi was associated with an indistinguishable clinical phenotype 
to that caused by wild-type S. Typhi (Extended Data Fig. 5).
To determine if absence of the typhoid toxin modulated host 
immune responses to infection, we measured T-cell and anti-
body-secreting cell (ASC) responses between challenge groups. 
Interferon-γ (IFN-γ)-producing T-cell responses to peptide pools 
comprising the typhoid toxin subunits CdtB, PltA and PltB were 
detectable in participants challenged with the wild-type strain, but 
not the TN strain, and peaked at day 28 post-challenge (Fig. 4). We 
observed a significant increase in circulating ASCs specific to the 
S. Typhi surface antigens O9:LPS and Hd at the time of typhoid 
diagnosis in both challenge groups (Extended Data Fig. 6) (ref. 13). 
The magnitude of the O9:LPS-antigen- and Hd-antigen-specific 
ASC response at typhoid diagnosis was generally greater in partici-
pants challenged with the TN strain. In particular, S. Typhi O9:LPS-
specific immunoglobulin A ASC responses at the time of typhoid 
diagnosis were significantly increased in the TN group (Fig. 4).
We next aimed to determine if the presence or absence of typhoid 
toxin was associated with a distinct plasma cytokine profile, mea-
sured using a 62-plex bead-based cytokine platform (Luminex) at 
baseline and during acute typhoid disease (Fig. 4). At the time of 
typhoid diagnosis, the plasma cytokines 10 kDa interferon-gamma-
induced protein (IP-10), monokine induced by interferon-gamma 
(MIG) and interleukin-1 receptor antagonist protein (IL-1RA) were 
significantly increased relative to baseline in both groups (Fig. 4). 
Hierarchical clustering and principal component analysis showed 
no separation of challenge groups by cytokine profile during 
acute typhoid disease (Fig. 4). Following adjustment for multiple 
testing, linear modeling found no cytokines to be significantly 
different between groups, although interleukin 8 (IL-8) was mar-
ginally downregulated in the toxin-negative but not the wild-type 
group (Fig. 4).
These data suggest that the typhoid toxin is not essential for 
S. Typhi infection nor the early acute presentation of typhoid fever. 
This study represents the first application of a typhoid human chal-
lenge model to prospectively study the role of a specific virulence 
factor in the pathogenesis of typhoid fever. Previous trials of live-
attenuated S. Typhi vaccines have offered insights into the impor-
tance of other Salmonella genes to human disease (including aroC/
aroD, htrA, phoP, phoQ, ssaV and cya)20. Overall, in this study, the 
clinical presentation was indistinguishable between the TN and 
wild-type groups. Counterintuitively, there was a trend toward a 
more severe disease phenotype in the TN group, including a shorter 
time to diagnosis, higher number of cases meeting the criteria for 
severe enteric fever, elevated ASC response and prolonged duration 
of bacteremia. These observations suggest that the typhoid toxin 
may have an important role in modifying host immune responses 
to infection.
These data raise questions as to the utility of targeting typhoid 
toxin in the development of novel therapeutics or vaccine strate-
gies. Notably, currently utilized typhoid vaccines, including Vi cap-
sular polysaccharide/conjugate vaccines, are capable of inducing 
protection despite targeting a virulence factor that is not strictly 
necessary for the establishment of enteric fever21–23. Antibody and 
T-cell responses to typhoid toxin components have been detected in 
patients with typhoid fever24–27. Further studies are required to cor-
relate host responses to typhoid toxin with protection against dis-
ease and to further characterize its function in the context of natural 
S. Typhi infection.
We acknowledge the limitations of our experimental approach. 
Due to ethical considerations, this model is not suited to assess the 
role of typhoid toxin in severe typhoid fever, including typhoid 
encephalopathy, which has been associated with typhoid toxin in 
animal models4,8. The primary diagnostic criteria minimizes risk to 
study participants by early treatment initiation7, but could mask dif-
ferences between groups by treating self-limiting disease. The study 
population may not be generalizable to typhoid endemic countries, 
owing to differences in prior immune-priming and/or baseline 
genetic differences28.
The absence of experiments showing reversion to virulence after 
complementation of the typhoid toxin genes in vitro is a limitation of 
this study. Additional studies with a strain expressing inactive com-
ponents of typhoid toxin (for example, cdtBH160Q, pltBS35A, pltAE133A) 
could address whether deletion of typhoid toxin genes is associated 
with an altered phenotype beyond loss of toxicity. Importantly, the 
study was underpowered to detect anything other than a large effect 
size (80% power to detect at 72% relative reduction). Additional 
in vitro studies and deeper analysis of challenge samples are ongo-
ing to further characterize the potential immunobiological role of 
typhoid toxin in the pathogenesis of typhoid fever.
These data indicate that typhoid toxin is not essential for the 
development of early acute typhoid fever within the context of a 
controlled human infection model. These data highlight some of the 
benefits and challenges of studying bacterial virulence factors using 
controlled human infection models, in particular for the screening 
of potential vaccine and therapeutic targets.
Online content
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Methods
Study design and participants. The OVG2016/03 (TYGER) study was a 
randomized, double-blind, controlled human infection study comparing the 
response to challenge with wild-type S. Typhi with a typhoid toxin-deficient 
isogenic mutant strain S. Typhi (SB6000). The study was designed as an outpatient 
challenge study, conducted in a cohort of healthy community adult volunteers in a 
setting non-endemic for typhoid fever (Oxford).
Challenge strains. To facilitate comparisons with earlier challenge studies7,13,14 
and to minimize the risk to study participants, we used the S. Typhi Quailes strain 
(genotype 3.0.1 (ref. 15)) as the parent strain to generate the typhoid toxin-deficient 
knockout strain. Deletion of typhoid toxin subunit genes was carried as  
described previously16.
Briefly, deletion of typhoid toxin subunit genes was carried out using the R6K-
derived, suicide vector pSB890. The pSB890 plasmid cannot replicate in S. Typhi 
since it requires the bacteriophage λpir protein to replicate. The plasmid vector also 
encodes a counterselectable marker sacB, which encodes an enzyme that is lethal 
to bacteria when grown in the presence of sucrose. The pSB890 plasmid vector 
is maintained in a specially constructed strain of Escherichia coli, which encodes 
the bacteriophage λpir protein. This E. coli strain also carries a deletion mutation 
in the asd gene(∆asd), which encodes the aspartate-semialdehyde dehydrogenase 
required for peptidoglycan synthesis—growth of this strain will only occur in 
media supplemented with lysine diaminoheptanedioate.
Due to the genomic organization of the typhoid toxin pathogenicity island, 
the cdtB gene was deleted first, followed by simultaneous deletion of the pltA and 
pltB genes (encoded immediately adjacent to one another) in the ∆cdtB strain. 
Chromosomal DNA fragments encoding sequences upstream and downstream 
of the target genes were expanded by PCR and cloned into the pSB890 plasmid, 
maintained in the E. coli ∆asd λpir strain. The plasmid vector encoding the cloned 
sequences was then transferred to S. Typhi by conjugation, counterselecting 
the donor E. coli strain by plating the transconjugants in media lacking lysine 
diaminoheptanedioate (counterselecting for the donor E. coli). Transconjugants 
of S. Typhi possessing deletions of the toxin integrated into the chromosome were 
identified by plating in sucrose that counterselects for the plasmid vector. Colonies 
were screened by PCR to identified mutants carrying the specific deletions.
Challenge strains were manufactured to a GMP standard at the Walter Reed 
Army Institute of Research (Silver Spring) and stored as a frozen suspension in 
soya tryptone medium containing 10% sucrose at −80 °C before use.
Strain characterization. Growth curves of wild-type and toxin-deficient strains 
of S. Typhi were performed in lysogeny broth (LB) using wild-type and TN 
strains. Isolates were inoculated into 10 ml of LB and grown overnight in a shaking 
incubator at 200–220 r.p.m. and 37 °C. The following day, cultures were vortexed 
and diluted 1:10 in fresh LB (100 µl culture + 900 µl LB). The OD600 was read in 
a cuvette using a mini photospectrometer against an LB-only blank, multiplying 
by the dilution factor (×10) to give the actual OD of the overnight culture. The 
dilution required to reduce the culture OD to 0.05 in a 30 ml volume of LB was 
calculated using the following equation (equation (1)):
× = ×OD1 V1 OD2 V2
where OD1 is the OD of the overnight culture, V1 is the volume of the overnight 
culture to be added to the new mix; OD2 is theOD of the new inoculum (0.05) 
and V2 is the volume of new inocula (30 ml). The calculated volume of overnight 
cultures (V1) was added to 30 ml of fresh LB, the OD600 read to ensure the OD of 
the new culture was 0.05 and was subsequently returned to the shaking incubator. 
Samples of culture were removed from the incubator at regular intervals and the 
OD600 was measured in a 50:50 mix of the culture and fresh LB against an LB 
blank. OD600 readings were multiplied by the dilution factor (×2) to give values 
for the undiluted culture and plotted against time to give the growth curve.
Typhoid toxin activity. Activity of the typhoid toxin was assessed using previously 
published methods4,6. Briefly, Henle-407 intestinal epithelial cells were infected 
with wild-type Quailes or typhoid toxin-deficient SB6000 S. Typhi for 1 h. Cells 
were washed and culture medium containing gentamicin (50 μg ml−1) was added 
and then incubated for 2 h. Cell were then washed and medium containing 
5 μg ml−1 gentamicin was added and infection continued for 48 h. Cells were 
collected from dishes by trypsinization (subsequently neutralized with serum-
containing media). The cell suspensions were centrifuged for 5 min at 1500 r.p.m., 
the supernatant discarded and cell pellets resuspended in 0.5 ml of PBS at room 
temperature. Cell suspensions were slowly added to tubes containing 4 ml of cold 
90% ethanol solution with continuous mixing. Cells were kept in fixative for 2 h 
on ice. The fixed cells were collected by centrifugation and the fixative decanted 
thoroughly. The pellets were washed once with 5 ml PBS and the cell pellet was 
resuspended in 1 ml of a solution containing 0.1% Triton X-100, DNase-free 
ribonuclease A (20 mg ml−1) and propidium iodide (20 μg ml−1; Molecular Probes) 
in PBS. The stained cells were analyzed by flow cytometry with a FACStar Plus  
flow cytometer (BD Biosciences). Intoxicated cells showed a larger proportion of 
cells in the G2/M phase of the cell cycle and thus exhibited a larger amount of  
DNA content.
Cellular invasion assay. Henle-407 intestinal epithelial cells were infected with 
wild-type S. Typhi Quailes or the toxin-deficient SB6000 derivative for 2 h at three 
multiplicity of infection (MOI) levels (50,100 and 500). Cells were washed and 
gentamicin (50 μg ml−1) was added to the culture medium. After 2 h, cells were 
washed again, lysed and colony counts of both strains were determined by plating 
dilutions of the cell lysates. The invasive ability was expressed as the percentage of 
the bacterial inoculum that survived gentamicin treatment.
Comparison of the bacterial loads of S. Typhi Quailes ∆pltB, ∆pltA and ∆cdtB 
with S. Typhi Quailes cdtBH160Q, pltBS35A and pltAE133A. Strains used for comparison 
of the bacterial loads of S. Typhi Quailes ∆pltB, ∆pltA and ∆cdtB with S. Typhi 
Quailes cdtBH160Q, pltBS35A and pltAE133A were derived from S. Typhi Quailes 
and were constructed by standard recombinant DNA techniques as described 
previously16. CmaH−/− bloc3−/− mice, which are susceptible to S. Typhi infection32, 
were intraperitoneally infected with equal numbers (105 CFUs) of S. Typhi Quailes 
derivative mutant strains carrying either deletions in the pltB, pltA and cdtB genes 
(S. Typhi Quailes ∆pltB, ∆pltA and ∆cdtB) or expressing an inactivated version of 
typhoid toxin by virtue of catalytic mutations in its active subunits PltA and CdtB 
and a mutation in the receptor-binding site of PltB (S. Typhi Quailes cdtBH160Q, 
pltBS35A and pltAE133A). The strains were alternatively marked by a chloramphenicol 
(cmR) or kanamycin (kanR) resistance genes, as indicated, inserted within the 
STY4607 gene, which previous studies have shown not to affect virulence32. All 
animal experiments were conducted in accordance with protocols approved by 
Yale University’s Institutional Animal Care and Use Committee. Seven-to-ten week 
old cmaH−/− bloc3−/− mice were injected intraperitoneally with 105 CFUs each of 
the two strains. The inoculum was plated to confirm the equivalent ratio of the 
bacterial strains. Mice were killed at day 5 post-infection and the CFUs of each 
strain in the spleens of infected animals were determined by plating on LB plates 
containing chloramphenicol (30 µg ml−1) or kanamycin (50 µg ml−1).
Phenotypic characterization of the wild-type and TN strains comprised growth 
characteristics in liquid culture, agglutination, cellular invasion assays and cell 
intoxication assays4. Whole-genome sequencing using both the MiSeq (Illumina) 
and PacBio (Pacific Biosciences) platforms was performed by the Wellcome Sanger 
Institute (Hinxton). DNA for MiSeq sequencing was extracted using the Wizard 
Genomic DNA purification kit according to the manufacturer’s instructions33. 
Sequence reads were assembled using HGAP v.3 of the SMRT analysis software 
v.2.3.0 (Supplementary Information).
Establishment of challenge dose. Challenge agents were prepared in batches for 
a maximum of six participants at any one time. All work was performed in the 
containment level 3 facility at the Centre for Clinical Vaccinology and Tropical 
Medicine (Oxford) in a class II biological safety hood dedicated for challenge  
agent preparation.
Two GMP master stock vials of typhoid toxin-negative S. Typhi TN strain 
(BPR–1218-00, lot 1977; cell concentration 1 × 106) or wild-type S. Typhi Quailes 
strain (BPR–1218-00, lot 1977; cell concentration 9.8 × 105) were selected at 
random from stocks stored in a −80 °C freezer. Vials were thawed at room 
temperature for approximately 10 min and mixed by vortexing. The contents of 
two GMP master stock vials were transferred to a master stock tube and mixed 
for 6–10 s by vortexing. A 1:10 dilution in sodium bicarbonate was performed by 
transferring 1,600 μl from the tube labeled ‘master stock’ to a fresh 50 ml falcon 
labeled as ‘master stock 1:10’. To create the challenge inoculum of the toxin-
negative strain, 1.74 ml from the ‘master stock 1:10 dilution’ was transferred to a 
sterile culture flask containing 4.2 g sodium bicarbonate dissolved in 240 ml bottled 
mineral water (‘challenge flask’). The challenge inoculum for the wild-type strain 
was generated by transferring 1.85 ml from the 1:10 dilution into an equivalent 
challenge flask. The challenge agents were then prepared by transferring 30 ml 
from the challenge flask to prelabelled 50 ml falcon tubes, sealed and stored on ice.
The challenge dose was confirmed by pipetting 200 μl from the challenge dose 
onto six Tryptone Soya Agar plates (code no. PO0163A; Oxoid). The bacterial 
suspension was spread over the source of the agar using an L-shaped spreader and 
cultured in an incubator overnight at 37 °C, 5% CO2. On the following day, colonies 
were manually counted and checked by a second operator. The CFUs of the 
challenge inoculum were calculated by multiplying the mean of the CFU counts 
for the plates by the dilution factor of the volume plated (×150 for a total challenge 
inoculum of 30 ml for a plating of 0.2 ml (30/0.2 = ×150)).
Sodium bicarbonate was prepared by dissolving 2.1 g sodium bicarbonate in 
120 ml bottled mineral water.
Participant characteristics. Healthy adults aged 18–60 years, without prior 
residency in an enteric fever endemic country for ≥6 months, were considered 
eligible for enrollment. Key exclusion criteria included significant medical, surgical 
or psychiatric history and gallbladder disease. A full description of the inclusion 
and exclusion criteria is provided in the Nature Research Reporting Summary.
Randomization and masking. Participants were randomized 1:1 to challenge with 
either wild-type strain S. Typhi or toxin-negative strain S. Typhi (TN) in varying 
block sizes. Anti-Vi IgG was measured at screening using a commercial ELISA kit 
(VaccZyme; The Binding Site Ltd) according to the manufacturer’s instructions14. 
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Randomization was stratified by anti-Vi IgG measured (low (<7.4 EU ml−1) or high 
(≥7.4 EU ml−1)). The exception was a sentinel group of two participants who were 
randomized 1:1 to receive the wild-type strain or TN knockout strain using a block 
size of two. Randomization was performed at the prechallenge visit, one week 
before challenge. We generated a randomization list in STATA v.14.2 (StataCorp), 
which was implemented in the computerized randomization software Sortition 
(Nuffield Department of Primary Care, Clinical Trials Unit, University of Oxford), 
which matched a masked allocation group to each participant. The software 
generated a randomization number, corresponding to the challenge allocation 
group. A locked, challenge agent randomization allocation list was maintained 
by the study statistician and unblinded laboratory team responsible for challenge 
agent preparation.
The study was conducted double-blind from the time of randomization until 
participant unblinding, such that participants, and clinical or laboratory staff 
undertaking follow-up procedures, were unaware of challenge agent allocation. 
Both wild-type and TN strains were prepared suspended in sodium bicarbonate 
and had an indistinguishable appearance (transparent, colorless liquid).
Procedures. Participants fasted for 90 min before challenge. Two minutes before 
challenge, participants drank a sodium bicarbonate solution (2.1 g 120 ml−1) to 
neutralize stomach acid. The oral challenge inoculum was administered suspended 
in sodium bicarbonate (0.53 g 30 ml−1) and was kept on ice before administration 
within 3 h of preparation. Participants were observed for 90 min post-challenge. 
The challenge dose administered was 1–5 × 104 CFUs calculated as described 
previously7,13,14. Participants attended the clinical site 12 h after challenge and then 
daily for 14 d, as described previously7. Daily visits comprised continued consent 
check, oral temperature measurement, heart rate and blood pressure measurement 
and sample collection, as outlined in the study protocol.
Solicited symptoms and twice-daily temperature measurements were recorded 
in an electronic diary for 21 d after challenge. Symptoms were categorized as not 
present, mild, moderate or severe (Supplementary Information).
Antibiotic treatment was initiated on fulfillment of composite diagnostic 
criteria or at day 14 for those without illness. First-line treatment was oral 
ciprofloxacin 500 mg twice daily for 14 d.
Outcomes. The primary objective of this study was to compare the proportion of 
participants meeting the composite diagnostic end point for typhoid fever (attack 
rate) following oral challenge with (1–5) × 104 CFUs wild-type S. Typhi Quailes 
strain, compared to challenge with (1–5) × 104 CFUs of a typhoid toxin-deficient 
isogenic mutant of S. Typhi Quailes strain SB6000 (TN). The composite diagnostic 
end point for typhoid fever was defined as a temperature ≥38 °C persisting for 
≥12 h and/or S. Typhi bacteremia collected ≥72 h after oral challenge.
Secondary end points were: mode of diagnosis; time to typhoid diagnosis; time 
to first temperature ≥38 °C; fever clearance time; time to bacteremia; duration of 
bacteremia; and quantitative blood culture (for definitions, see the Life Sciences 
Reporting Summary). Descriptive end points included: severe adverse events; 
solicited symptom profiles; proportion of participants meeting the criteria for 
severe enteric fever; hematological and biochemical measures; plasma cytokine 
profiles; pattern of bacteremia; and pattern of stool shedding (see Life Sciences 
Reporting Summary).
Stool samples for culture, blood samples for culture (10 ml), and hematological 
and biochemical testing were processed by the local hospital’s accredited pathology 
laboratory as described previously7.
Criteria for severe enteric fever. Severe enteric fever was defined as participants 
meeting any of the following criteria: oral temperature >40 °C; systolic blood 
pressure <85 mmHg; significant lethargy or confusion; gastrointestinal bleeding; 
gastrointestinal perforation; or any grade 4 laboratory abnormality34.
Ex vivo ASC enzyme-linked immune absorbent spot (ELISpot). Ex vivo IgG-, 
IgA- and IgM-producing ASC responses against O- and H-antigen were measured 
at baseline and 24–48 h after typhoid diagnosis in those meeting the diagnostic 
criteria as described previously13.
Multiscreen filtration ELISpot plates (catalog no. MAHAS4510; Merck 
Millipore) were coated with S. Typhi O9:LPS, S. Typhi Hd antigen (University 
of Maryland) and Pan goat anti-human immunoglobulin (catalog no. H17000; 
Invitrogen) each at a final concentration of 10 μg ml−1 in carbonate-bicarbonate 
buffer and incubated overnight at 4 °C. Plates were blocked with 200 μl per well of 
R10 medium for 1 h before use at 37 °C, 5% CO2. Peripheral blood mononuclear 
cells (PBMCs) were separated using ACCUSPIN tubes (Sigma-Aldrich), counted 
and resuspended in R10 media. PBMCs at a concentration of 2.5 × 105 were 
added in duplicate to the ELISpot plate (100 μl per well) and incubated overnight 
at 37 °C, 5% CO2. Plates were washed four times with PBS-0.25% Tween, once 
with PBS and soaked with PBS for 5 min. Goat anti-human IgG, IgA and IgM 
secondary antibodies conjugated to alkaline phosphatase (catalog nos. 401442, 
401132 and 401902, respectively; Sigma-Aldrich) were diluted to 1:5,000 in PBS/
FBS and incubated for 4 h at room temperature. After incubation, the plates were 
washed five times with PBS-0.25% Tween and four times with dsH2O. Alkaline 
phosphatase substrate (catalog no. 170-6432; Bio-Rad) was added at 50 μl per well, 
allowed to develop over approximately 10 min and stopped with dsH2O as spots 
began to develop.
ELISpot plates were read using an automated ELISpot reader (ELR03/
ELR030408215; Autoimmun Diagnostika) and the AID ELISpot software v.5.0. 
Study- and antigen-specific count settings for spot intensity, size and gradient were 
applied to the plate counts and manually verified to remove artifacts. Raw counts 
(spots per 2.5 × 105 PBMCs) were averaged across duplicate wells and multiplied by 
four to give the number of spot-forming units (SFUs) per 106 PBMCs.
Fluorospots. Measurements were taken from frozen PBMCs collected at baseline, 
and on day 14 and 28 post-challenge. Precoated plates (catalog no. FSP-010308-10; 
Mabtech) were blocked before adding 50 µl per well toxin peptide pools consisting 
of 15-mer sequences with 11-amino acid overlaps and covering the sequence of 
proteins CdtB, PltA and PltB (thinkpeptides). The peptides were dissolved in 100% 
DMSO (Sigma-Aldrich) and arranged in three pools. Concentration was adjusted 
at 0.6 mg ml−1 and used in the fluorospot assay at a final concentration of 3 µg ml−1 
of each peptide. DMSO and concanavalin A (Sigma-Aldrich) were used as negative 
and positive controls, respectively. After defrosting and resting for 1 h, 50 µl 
per well of PBMCs were added to the peptide wells at a concentration of 4 × 106 
cells ml−1 in triplicate and incubated overnight at 37 °C, 5% CO2, 95% humidity. 
Detection of spots was carried out according to the manufacturer’s instructions 
(Mabtech) and analyzed with the iSpot EliSpot reader (Autoimmun Diagnostika).
Plasma cytokine analysis. Plasma was isolated from heparinized blood by 
centrifugation. Protease inhibitor was added in a 1:40 dilution before storage at 
−80 °C. Longitudinal cytokine quantification was carried out for all 40 challenged 
participants by the Human Immune Monitoring Center at Stanford University 
using a 62-plex Luminex system (brain-derived neurotrophic factor, beta-nerve 
growth factor, CD40 ligand, epidermal growth factor, ENA-78 (CXCL5), eotaxin, 
fibroblast growth factor 2, granulocyte-colony-stimulating factor, granulocyte-
macrophage colony-stimulating factor, GRO-α (CXCL1), hepatocyte growth factor, 
IFN-α, IFN-β, IFN-γ, IL-1-α, IL-1-β, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, 
IL-17A, IL-17F, IL-18, IL-1RA, IL-2, IL-21, IL-22, IL-23, IL-27, IL-31, IL-4, IL-5, 
IL-6, IL-7, IL-8, IL-9, IP-10, leptin, leukemia inhibitory factor, macrophage colony-
stimulating factor 1, monocyte chemoattractant protein 1 (MCP-1), MCP-3, MIG, 
macrophage inflammatory protein-1-α (MIP-1-α), MIP-1-β, plasminogen activator 
inhibitor 1, platelet-derived growth factor subunit B, RANTES, resistin, stem 
cell factor, stromal cell-derived factor 1, soluble Fas ligand, soluble intercellular 
adhesion molecule 1, soluble vascular cell adhesion protein 1, transforming 
growth factor-α (TGF-α), TGF-β, tumor necrosis factor-α (TNF-α), TNF-β, 
tumor necrosis factor ligand superfamily member 10, vascular endothelial growth 
factor A (VEGF-A) and VEGF-D). Samples were run in duplicate and the mean 
fluorescence intensity (MFI) of duplicates was used for analysis. To minimize plate-
to-plate variation, samples across time points for each individual were run on the 
same plates and each plate contained an equal mix of individuals allocated to wild-
type or toxin-negative challenge. Control beads (CHEX 1–4) and control sera were 
used per plate.
The MFI of all samples were examined by principal component analysis to 
confirm consistency between duplicates and identify outliers. One participant 
was excluded on this basis. Duplicates were then averaged and the MFI quantile 
normalized. Significance testing was performed using linear modeling in limma 
v3.34.9 (ref. 35), incorporating plate, dose and sex as covariates. P values were 
corrected for multiple testing using the Benjamin–Hochberg correction. Hierarchal 
clustering was carried out based on Euclidean distance.
Sample size. The sample size was dictated primarily by the number of participants 
that could be feasibly enrolled within the time frame and budget of the study; 
therefore, it represents a convenience sample. Assuming typhoid toxin is central 
to the clinical presentation of acute typhoid fever, it was anticipated that the attack 
rate following challenge with the TN strain would be reduced compared with 
the wild-type strain, although the effect size was unknown. Assuming an attack 
rate of 65% following wild-type challenge (as observed in previous studies) and 
50% attack rate following TN challenge, and accounting for a 10% dropout, 20 
participants in each group had 95% CIs for attack rate of 41–85% in the wild-type 
group and 27–73% in the TN group. Twenty participants per arm provided 95% 
power to detect an absolute reduction in attack rate of 55% (65% with the wild-
type strain versus 10% with the TN strain, corresponding to an 85% relative risk 
reduction) and 80% power to detect an absolute reduction in attack rate of 47% 
(65% with the S. Typhi wild-type strain versus 18% with the S. Typhi toxin-negative 
strain, corresponding to a 72% relative risk reduction) based on Fisher’s exact test 
with 5% alpha.
Statistical considerations. Attack rates and 95% CIs were calculated for each 
challenge group for the per-protocol population (that is, participants who 
completed the 14-d challenge period) as the primary end point. All participants 
were included in the analyses if they were successfully challenged on day 0 and 
had at least one post-challenge assessment. The difference in attack rate (and 
other categorical variables) between naïve and rechallenge groups was tested using 
Fisher’s exact test. Time-to-event data were summarized using the Kaplan–Meier 
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method, with participants censored at day 14. Group comparisons were performed 
using a log-rank test. Continuous variables were compared using the Mann–
Whitney U-test for unpaired samples and the Wilcoxon signed-rank test for paired 
samples. All statistical tests were two-sided.
Paired samples across time points were compared using the Wilcoxon signed-
rank test. Comparisons between groups were performed using the Mann–Whitney 
U-test. ELISpot/FluoroSpot data were log10-transformed to approximate a 
normal distribution; wells with no spots were assigned an arbitrary value of 0.5, 
corresponding to half the lower limit of detection. Raw counts were averaged 
across replicate wells. The number of background spots detected in blank wells 
were subtracted from the test samples to give the final cell count per sample.
Clinical data were recorded on a web-based database (OpenClinica Enterprise 
v3.13). Symptom and ELISpot were extracted using Microsoft Excel. Data analysis 
was performed using R v.3.4.4. Variables were normalized by z-score before 
inclusion in the principal component analysis, which was performed using the 
FactoMineR package v1.41 (ref. 36).
Approvals. The OVG2016/03 study was sponsored by the University of Oxford 
(Clinical Trials & Research Governance). Ethical approvals for the primary 
protocol, and any study amendments, were obtained from the South Central-
Oxford A Research Ethics Committee (16/SC/0358). In the UK, legislation 
governing the deliberate release of genetically modified organisms is currently 
provided by the Environmental Protection Act 1990, sections 111 and 112 (ref. 37), 
and the Genetically Modified Organisms (Deliberate Release) Regulations 2002 
(ref. 38). Approvals for deliberate release of the genetically modified strain of S. 
Typhi were obtained from the United Kingdom Department for Environment, Food 
& Rural Affairs (16/R48/01) (ref. 39). The study was registered with clinicaltrials.gov 
(NCT03067961) and was performed according to the provisions of the Declaration 
of Helsinki (2013) and Good Clinical Practice guidelines. This work is licensed 
under the Creative Commons Attribution 4.0 International License.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The datasets generated and/or analyzed during the current study are attached. 
Any additional data are available from the corresponding author. No participant 
identifiable information will be disclosed.
The raw sequence reads for the wild-type and TN strains used in the challenge are 
available under accession nos. ERS3381923 and ERS3381927.
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Extended Data Fig. 1 | Trial profile. One participant randomized to wild-type S. Typhi withdrew before challenge and was excluded from all further 
analyses, leaving 40 participants in the per-protocol analysis.
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Extended Data Fig. 2 | Baseline anti-Vi IgG. S. Typhi Quailes strain (n = 21). Two-sided Mann–Whitney U-test. The box plots represent the median and 
IQR. The overlaid violin plots illustrate the distribution of the data points and their probability density. Samples below the lower limit of detection of the 
ELISA (7.4 EU ml−1) were assigned a value equating to half the lower limit of detection (3.7 EU ml−1)14. The box plots display the median and IQR, with the 
upper whiskers extending to the largest value ≤1.5 × IQR from the 75th percentile and the lower whiskers extending to the smallest values ≤1.5 × IQR from 
the 25th percentile. The overlaid violin plots illustrate the distribution of the data points and their probability density31. TN S. Typhi (n = 19).
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Extended Data Fig. 3 | Hematological and biochemical laboratory measures after challenge. Participants challenged with TN (red) and wild-type 
(blue) S. Typhi and diagnosed with typhoid fever, nTN = 15, nWild-type = 15. Data are presented relative to the time of typhoid diagnosis (time point 0 = day of 
diagnosis). The dot plots corresponds to individual values colored according to challenge group (TN, red; wild-type, blue). The solid, colored lines connect 
the median values at each time point. The dashed lines represent the upper and lower reference limits for the individual parameters measured. The box 
plots display the median and IQR, with the upper whiskers extending to the largest value ≤1.5 × IQR from the 75th percentile and the lower whiskers 
extending to the smallest values ≤1.5 × IQR from the 25th percentile31, and are colored according to challenge group.
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Extended Data Fig. 4 | Principal component analysis (PCA) biplot of disease severity by outcome of challenge. Participants challenged with TN (n = 19) 
or wild-type (n = 21) S. Typhi based on the typhoid severity score. The data points are colored by outcome of challenge (yellow, typhoid diagnosis; blue, 
no typhoid diagnosis). The ellipses represent the 95% confidence levels for diagnosis status. The biplot arrows represent the contributions of individual 
variables to a given principal component, scaled according to their relative contribution36.
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Extended Data Fig. 5 | PCA biplot of disease severity by challenge agent. PCA biplot of participants challenged with typhoid fever following challenge 
with TN (n = 19) or wild-type (n = 21) S. Typhi based on all clinical, microbiological and laboratory measures. The data points are colored by challenge 
agent allocation. The ellipses represent the 95% confidence levels for challenge agent. The biplot arrows represent the contributions of individual variables 
to a given principal component, scaled according to their relative contribution36.
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Extended Data Fig. 6 | 09:LPS- and Hd-specific IgG, IgA and IgM ex vivo ASC responses. a, 09:LPS. b, Hd. Participants diagnosed with typhoid, illustrated 
as log10 SFUs per 106 PBMCs. D0, baseline; TD, time of diagnosis (samples processed 24–48 h after initiation of treatment). Two-sided matched-pairs 
Wilcoxon signed-rank test. nWild-type = 11, nTN = 10. The box plots display the median and IQR, with the upper whiskers extending to the largest value 
≤1.5 × IQR from the 75th percentile and the lower whiskers extending to the smallest values ≤1.5 × IQR from the 25th percentile.
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Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency 
in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection Clinical data were recorded on a web-based database (OpenClinica Enterprise). Symptom and ELISPOT/Flurospot were extracted using 
Microsoft Excel. ELISPOT plates were read using an automated ELISPOT reader (AID ELR03/ELR030408215) and AID ELISPOT software 
V5.0. 
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Data analysis Data analysis was performed using R version 3.4.4. Plots were generated using the ggplot2 package. . The principal component analysis 
was performed using the FactoMineR package 37 with R version 3.4.4. 
The randomisation list was generated in STATA version 14.2.  
Randomisation was implemented using Sortition® (Oxford University Innovation Ltd & Nuffield Department of Primary Care, Clinical Trials 
Unit, University of Oxford). 
 
Sequencing: 
Sequence reads were assembled using HGAP v3 (PMID: 23644548) of the SMRT analysis software v2.3.0 (Available from: https://
github.com/PacificBiosciences/SMRT-Analysis).  
The assembly was circularized using Circlator v1.1.3 (PMID: 26714481).  
The circularized assembly was polished using the PacBio RS_Resequencing protocol and Quiver v1 of the SMRT analysis software v2.3.0 
(Available from: https://github.com/PacificBiosciences/SMRT-Analysis). 
Automated annotation, as well as annotation steps on manual assemblies, was performed using PROKKA v1.11 [(PubMed PMID: 
24642063) and a genus specific databases from RefSeq (PubMed PMID: 22121212).  
 
SNP/Indel calling 
The in-house script uses SMALT v0.7.4 (Available from: https://sourceforge.net/projects/smalt/) to map reads against a selected 
reference including randomly mapping the repeats and using the GATK indel alignment option. Variation detection was performed using 
samtools mpileup v0.1.19 and bcftools v0.1.19 to produce a BCF file of all sites and all variant sites.  
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author. No participant identifiable information will be 
disclosed.  
 
The raw sequence reads are available under accessions ERS3381923 (sample 1 Oxford w/t), ERS3381924 (sample 2 w/t Pre-GMT), ERS3381925 (sample 3 w/t Post-
GMT), ERS3381926 (sample 4 k/o Pre-GMT), and ERS3381927 (sample 5 k/o Post-GMT). Manually refined hybrid assemblies as described above are given for the 
wild type strain (sample 2 w/t Pre-GMT) under accession GCA_901457615 and for the knock-out strain (sample 5 k/o Post-GMT) under accession GCA_901457625.
Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size The number of participants enrolled represents a convenience sample, reflecting the number of participants that could be feasibly enrolled 
within the time-frame and budget of the study. Assuming that the typhoid toxin is central to the clinical presentation of acute typhoid fever, it 
was anticipated that the attack rate following challenge with the TN strain would be reduced compared with the WT strain, although the 
effect size was unknown. 
 
Assuming an attack rate of 65% following WT challenge  and 50% attack rate following TN strain, and accounting for 10% drop out, 20 
participants in each group gave 95% confidence intervals for attack rate of 41% to 85% in the WT group and 27% to 73% in TN group. Twenty 
participants per arm provided 95% power to detect a relative risk reduction in attack rate of 85% (65% with WT strain versus 10% with TN 
strains) and 80% power to detect a relative reduction in attack rate of 72% (65% with S. Typhi wild type strain versus 18% with S. Typhi toxin-
negative) based on Fisher’s Exact test with 5% alpha
Data exclusions One participant randomized to wild-type S. Typhi declined to participate after enrolment, but prior to challenge, and was excluded from all 
further analyses. 
Replication Participants acted as biological replicates within study groups.  
Permission for deliberate release of the genetically modified toxin-negative strain of S. Typhi was given for a limited number of participants 
(n=20) and precluded replication in an independent cohort. 
Randomization Participants were randomized 1:1 to challenge with either wild-type strain Salmonella Typhi (WT) or toxin-negative strain Salmonella Typhi 
(TN) in varying block sizes. 
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 Anti-Vi IgG was measured at screening using a commercial ELISA kit (VaccZyme, The Binding Site Ltd, Birmingham, UK) according to the 
manufacturer’s instructions. Randomization was stratified by anti-Vi IgG (low <7.4EU/ML or high =>7.4EU/ml. The exception was a sentinel 
group of two participants who were randomized 1:1 to receive the WT strain or TN knock-out strain, using a block size of two. 
 
Randomization was performed at the pre-challenge visit (Day -7), one week prior to challenge. We generated a randomisation list in STATA 
version 14.2, which was implemented in the computerised randomisation software Sortition (Nuffield Department of Primary Care, Clinical 
Trials Unit, University of Oxford), which matched a masked allocation group to each participant.  
Blinding The study was conducted in a double-blind from the time of randomisation until participant unblinding, such that the participants, and clinical 
or laboratory staff undertaking follow-up procedures, were unaware of challenge agent allocation. Both WT and TN strains were prepared 
suspended in sodium bicarbonate and had an indistinguishable appearance (transparent, colourless liquid).
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials & experimental systems
n/a Involved in the study
Antibodies
Eukaryotic cell lines
Palaeontology
Animals and other organisms
Human research participants
Clinical data
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Antibodies
Antibodies used Antibodies:  
Manufacturer: Merck Millipore 
Catalog/lot number: Goat anti-human IgG γ-Chain specific conjugated to alkaline phosphatase 401442-1ml/2689825;  
Goat anti-human IgA alpha-Chain specific conjugated to alkaline phosphatase 401132/D00165538.  
Used at a 1:5000 dilution. 
 
Flurospot detection antibodies, using Mabtech kit FSP-010308-10 (batch 3). 
Manufacturer: Mabtech 
Anti IFNg monoclonal antibody, clone 7-B6-1-BAM, batch 1, 1/200 dilution  
Anti IL17A monoclonal antibody biotinylated, clone MT504, batch 7, 1/250 dilution 
Fluorophore conjugates:  
anti BAM-490, batch 3, 1/200 dilution; SA-550, batch 7, 1/200 dilution; anti-WASP-641, batch 7, 1/200 dilution 
 
 
Validation Immunoaffinity purified goat polyclonal anti-human IgA and anti-human IgG antibody conjugated to alkaline phosphatase, 
validated by manufacturer Merck Millipore. 
(Manufacturers information available at http://www.merckmillipore.com/GB/en/product/Goat-Anti-Human-IgG-Chain-Specific-
Alkaline-Phosphatase-Conjugate,EMD_BIO-401442#anchor_PDS) 
 
Antibodies used in flurospot assay validated by manufacturer Mabtech. 
(Manufacturers information available at https://www.mabtech.com/products/anti-human-ifn-gamma-antibody-7-b6-1-
biotinylated-3420-6) 
 
Antibodies used in ex-vivo ELISPOT assays as outlined in  https://www.ncbi.nlm.nih.gov/pubmed/18032593 and https://
www.ncbi.nlm.nih.gov/pubmed/27533046 
 
 
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) Henle-407 intestinal epithelial cells from the Roy Curtiss laboratory collection.
Authentication The cells were frequently checked for their morphological features, growth speed and functionalities, but were not 
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Authentication authenticated by short tandem repeat (STR) profiling.
Mycoplasma contamination All cell lines tested negative for mycoplasma contamination.
Commonly misidentified lines
(See ICLAC register)
No commonly misidentified cell lines were used.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals CmaH -/- bloc3 -/- mice (Figure 1).  
Age: 7 -10 week old 
Sex: male and females, randomly assigned to the different groups
Wild animals The study did not involve wild animals.
Field-collected samples The study did not involve field collected specimens.
Ethics oversight All animal experiments were conducted according to protocols approved by Yale University’s Institutional Animal Care and Use 
Committee. 
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Human research participants
Policy information about studies involving human research participants
Population characteristics Healthy adults aged 18-60 years 
 
 
Key exclusion criteria included significant medical, surgical or psychiatric history, gallbladder disease and high-risk occupations as 
defined by Public Health England guidelines. A full description of inclusion and exclusion criteria is provided in the attached study 
protocol and below.  
 
Study eligibility  
Male or female participants aged 18-60 years inclusive who were in good health (as determined by a study doctor, medical 
investigation and review of medical history provided by their General Practitioner) and who were able to provide written 
informed consent were eligible for inclusion in this study. 
 
Inclusion Criteria 
Participants must satisfy all of the following criteria to be considered eligible for the study: 
• Agree to give informed consent for participation in the study. 
• Aged between 18 and 60 years inclusive at time of challenge. 
• In good health as determined by medical history, physical examination and clinical judgment of the study team. 
• Agree (in the study team’s opinion) to comply with all study requirements, including capacity to adhere to good personal 
hygiene and infection control precautions. 
• Agree to allow his or her General Practitioner (and/or Consultant if appropriate), to be notified of participation in the study. 
• Agree to allow study staff to contact his or her GP to access the participant’s vaccination records and summary of medical 
history. 
• Agree to allow Public Health England to be informed of their participation in the study. 
• Agree to give his or her close contacts written information informing them of the participant’s involvement in the study and 
offer them voluntary screening for S. Typhi carriage. 
• Agree to have 24-hour contact with study staff during the four weeks post challenge and to be able to ensure that they are 
contactable by mobile phone for the duration of the challenge period until antibiotic completion. 
• Agree to allow the study team to hold the name and 24-hour contact number of a close friend, relative or housemate who will 
be kept informed of the study participant’s whereabouts for the duration of the challenge period (from the time of challenge 
until completion of antibiotic course). This person will be contacted if study staff are unable to contact the participant. 
• Have internet access to allow completion of the e-diary and real-time safety monitoring.  
• Agree to avoid antipyretic/anti-inflammatory treatment from the time of challenge (Day 0) until advised by a study doctor or 
until 14 days after challenge.  
• Agree to refrain from donating blood for the duration of the study. 
• Agree to provide their National Insurance/Passport number for the purposes of TOPS registration and bank account details for 
payment of reimbursement expenses. 
 
Exclusion Criteria 
Participants were not enrolled if any of the following applied: 
• History of significant organ/system disease that could interfere with trial conduct or completion. Including, for example, but 
not restricted to: 
o Cardiovascular disease 
o Respiratory disease  
o Haematological disease  
o Endocrine disorders 
o Renal or bladder disease, including history of renal calculi 
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o Biliary tract disease, including biliary colic, asymptomatic gallstones or previous cholecystectomy 
o Gastro-intestinal disease including requirement for antacids, H2-receptor antagonists, proton pump inhibitors or laxatives 
o Neurological disease 
o Metabolic disease 
o Autoimmune disease 
o Psychiatric illness requiring hospitalisation or known or suspected drug and/or alcohol misuse (alcohol misuse defined as an 
intake exceeding 42 units per week) 
o Infectious disease 
• Have any known or suspected impairment of immune function, alteration of immune function, or prior immune exposure that 
may alter immune function to typhoid resulting from, for example:  
o Congenital or acquired immunodeficiency, including IgA deficiency 
o Human Immunodeficiency Virus infection or symptoms/signs suggestive of an HIV-associated condition 
o Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months 
or long-term systemic corticosteroid therapy. 
o Receipt of immunoglobulin or any blood product transfusion within 3 months of study start.  
o History of cancer (except squamous cell or basal cell carcinoma of the skin and cervical carcinoma in situ). 
• Moderate or severe depression or anxiety as classified by the Hospital Anxiety and Depression Score at screening or challenge 
that is deemed clinically significant by the study doctors . 
• Weight less than 50kg . 
• Presence of implants or prosthesis. 
• Anyone taking long-term medication (e.g. analgesia, anti-inflammatories or antibiotics) that may affect symptom reporting or 
interpretation of the study results. 
• Contraindication to fluoroquinolone or macrolide antibiotics (e.g. ciprofloxacin or azithromycin). 
• Female participants who are pregnant, lactating or who are unwilling to ensure that they or their partner use effective 
contraception 30 days prior to challenge and until three negative stool samples have been obtained after completion of 
antibiotic treatment. 
• Full-time, part-time or voluntary occupations involving:  
o Clinical or social work with direct contact with young children (defined as those attending pre-school groups or nursery or aged 
under 2 years), or  
o Clinical or social work with direct contact with highly susceptible patients or persons in whom typhoid infection would have 
particularly serious consequences (unless willing to avoid work until demonstrated not to be infected with S. Typhi in accordance 
with guidance from Public Health England and willing to allow study staff to inform their employer). 
• Full time, part time or voluntary occupations involving: 
o Commercial food handling (involving preparing or serving unwrapped foods not subjected to further heating) 
• Close household contact with:  
o Young children (defined as those attending pre-school groups, nursery or those aged less than 2 years) 
o Individuals who are immunocompromised.  
• Scheduled elective surgery or other procedures requiring general anaesthesia during the study period. 
• Participants who have participated in another research study involving an investigational product that might affect risk of 
typhoid infection or compromise the integrity of the study within the 30 days prior to enrolment (e.g. significant volumes of 
blood already taken in previous study) . 
• Detection of any abnormal results from screening investigations (at the clinical discretion of the study team). 
• Inability to comply with any of the study requirements (at the discretion of the study staff and the participant’s General 
Practitioner). 
• Any other social, psychological or health issues which, in the opinion of the study staff, may 
o put the participant or their contacts at risk because of participation in the study, 
o adversely affect the interpretation of the primary endpoint data, 
o impair the participant’s ability to participate in the study. 
• Prior vaccination with an oral typhoid vaccines (e.g. Ty21a) or other investigational typhoid vaccine (e.g. Vi-conjugate vaccine, 
MO1ZH09)  
• Prior vaccination with a Vi-polysaccharide typhoid vaccine administered within 5 years from the time of screening.   
• Prior vaccination with a Vi-polysaccharide typhoid vaccine administered more than 5 years from the time of screening AND 
detectable Vi-antibody titre at screening (defined as IgG ≥7.4U/ml measured using the VaccZyme Salmonella Typhi Vi IgG kit, 
Binding Site ® UK). 
• Having been resident in an enteric fever endemic country for 6 months or more. 
• Have previously been diagnosed with laboratory-confirmed typhoid or paratyphoid infection or been given a diagnosis 
compatible with enteric fever. 
• Have participated in previous typhoid or paratyphoid challenge studies (with ingestion of challenge agent). 
• Have a prolonged corrected QT interval (>450 milliseconds) on ECG screening.  
 
Recruitment Identification of study participants 
Several strategies were employed to recruit participants, including: 
 
-NHS database: Potential study participants will be identified via databases such the National Health Applications and 
Infrastructure Services (NHAIS) who hold the central NHS patient database (Open Exeter) or their equivalent.  
 
-Poster advertising: Display of posters advertising the study throughout local hospitals and doctor’s surgeries, tertiary education 
institutions and other public places with the permission of the owner/ proprietor. 
 
-Direct mail-out 
 
-E-mail communication: We will contact representatives of local tertiary education establishments and local employers and ask 
them to circulate posters and information, and to circulate a link to study information on the OVG website by email. 
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-Oxford Vaccine Centre (OVC) database for healthy volunteers 
 
-Media advertising: Local media, newspaper, radio, website and social media advertisement placed in locations relevant for the 
target age group with brief details of the study and contact details for further information 
 
-Website advertising: Description of the study and copy of information booklet on the Oxford Vaccine Group website. 
 
Exhibitions: Advertising material and/or persons providing information relating to the study will exhibit using stalls or stands at 
exhibitions and/or fairs, such as University  Fairs 
 
Royal Mail Leaflet: Royal Mail door-to-door service with delivery of invitation letters in OVG envelopes to every household within 
certain postcode areas. 
 
Potential participants who were interested in study participation contacted the study site by telephone, email, by out  website 
online registration with self-screening questions or paper reply slip for further information. Once an expression of interest was  
received, an information booklet was be sent via mail or email to the potential participants to read at their leisure. Participants 
were also be directed to the Oxford Vaccine Group website, where the information booklet was available. If participants were 
willing to proceed they were invited for a screening and consent visit, where a member of the clinical research team at the 
Oxford Vaccine Group assessed their eligibility. We also took consent for clinical staff to access electronic patient records (EPR) 
to assess eligibility. 
We acknowledge the potential self-selection bias in  such  human-challenge studies. We contend that t any potential biases are 
mitigated by standardized procedures and consistent inclusion/exclusion criteria. These limitations are discussed within the 
manuscript. 
Ethics oversight The OVG2016/03 study was sponsored by the University of Oxford (Clinical Trials & Research Governance). Ethical approvals for 
the primary protocol, and any study amendments, were obtained from the South-Central Oxford A research ethics committee 
(16/SC/0358). In the UK, legislation governing the deliberate release of genetically modified organisms is currently provided by 
the Environmental Protection Act 1990 section 111 and 11242, and the Genetically Modified Organisms (Deliberate Release) 
Regulations 200243. Approvals for deliberate release of the genetically modified strain of S. Typhi were obtained from the 
United Kingdom Department for Environment, Food & Rural Affairs (16/R48/01)44
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Clinical data
Policy information about clinical studies
All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.
Clinical trial registration  Clinicaltrials.gov NCT03067961
Study protocol Submitted alongside manuscript
Data collection Centre for Clinical Vaccinology & Tropical Medicine, The Churchill Hospital, Oxford, United Kingdom 
OX3 7LE 
10th April 2017 and 1st August 2017
Outcomes Primary Outcome Measure 
 
The primary outcome was the attack rate post challenge, defined as the proportion of participants meeting the composite 
diagnostic endpoint for typhoid fever during the challenge period.   
The composite diagnostic endpoint for typhoid fever was defined as a  temperature of  38C persisting for >12hrs and/or S. Typhi 
bacteraemia collected >72hours after oral challenge 
  
 
Secondary clinical and microbiological outcome variables are listed by below  
 
• Time to diagnosis - Time from date/time of challenge to date/time of first temperature >38C that subsequently lasted for 
>12hours OR the date/time of first positive blood culture collection (whichever occurs earliest).  
• Time to first blood culture positive for S. Typhi- Time from date/time of challenge to date/time of blood culture collection.  
• Time to clinical diagnosis (fever >38C lasting >12 hours) - Time from date/time of challenge to date/time of first recorded 
temperature >38C which subsequently lasted 12 hours.  
• Mode of diagnosis - The proportion of participants diagnosed with typhoid/paratyphoid fever based upon either clinical criteria 
(persistent fever >38C for >12 hours) OR microbiological criteria (blood culture positive for S. Typhi collected >72 hours from 
diagnosis) 
• Detailed mode of diagnosis - Proportion of participants diagnosed with typhoid/paratyphoid fever based upon either of the 
following specific diagnostic criteria: 
Temperature >38C preceding positive blood culture; 
o Temperature >38C without positive blood culture; 
o S. Typhi bacteraemia preceding temperature >38C;   
o S. Typhi bacteraemia without temperature >38C.  
• Time to first fever - Time from date/time of challenge to date/time of first recorded temperature >38C.  
• Fever clearance time - Time from initiation of antibiotics or start of fever (whichever was later) to first recorded temperature 
<38oC persisting for at least 48hours. Only diagnosed participants with fever were included in the analysis. 
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• Symptom severity - Severity of symptoms in each challenge group were assessed by: 
o The proportion of participants with maximum symptom severity score graded as mild, moderate or severe following challenge. 
o The proportion of participants meeting the criteria for severe enteric fever.  
o Individual enteric fever severity scores calculated by summing numerical values assigned to the severity of individual solicited 
symptoms, clinical observations (heart rate, systolic blood pressure, diastolic blood pressure and temperature) and laboratory 
measurements between Day 0 to Day 21 (0=not present; 1=mild; 2=moderate; 3=severe; 4 = Hospitalisation. 
o Duration of bacteraemia - Time (Hours/Days) from collection of first positive blood culture until date/time of the last positive 
blood culture. 
o Bacteraemia clearance time - Time (Hours/Days) from collection of first positive blood culture until date/time of the first 
negative blood culture remaining persistently negative. Participants with missing data (e.g. no negative blood cultures after 
commencing antibiotics) were censored in the analysis at the time point of the last culture taken. 
o Stool shedding - Daily stool culture(s) positive for S. Typhi for 14 days post-challenge.  
• Quantitative blood culture - Concentration of bacteria in 10ml blood taken at the time of diagnosis using the Wampole™ 
Isostat® Isolator system (Colony forming units/ml). For values below the lower limit of detection (0.1 CFU/ml), a value of 0.05 
CFU/ml was assigned. 
• Haematological and biochemical end-points - The following haematological parameters were measured from time of challenge 
to Day 28 and/or Day 90. 
o Total Haemoglobin (g/L) 
o Haemoglobin change from baseline (Hb g/l D0 – Hb g/l D14) 
o Total White Cell Count (x109/l) 
o Platelet counts (x109/l) 
o Neutrophil count (x109/l) 
o Lymphocyte count (x109/l) 
o Monocyte count (x109/l) 
o Eosinophil count (x109/l) 
o Monocyte/Lymphocyte ratio 
o Urea & Electrolytes (Na, K+, Urea, Creatinine –mmol/l) 
o C-reactive protein (mg/l) 
o Liver function tests (Bilirubin [umol/l], aspartate transaminase (AST IU/l), alkaline phosphatase (ALP IU/l), alanine transaminase 
(ALT IU/l), Albumin (g/L) 
• Safety outcome measures - Adverse events, adverse events of special interest, SAE’s and SUSARs according to each study 
group.  
